UltraSight Raises $24 Million to Scale Its AI-Guided Cardiac Workflow Platform Across U.S. Health Systems

Financing builds on FDA clearances, clinical evidence and commercial traction to advance the UltraSight Echosystem and broaden cardiovascular partnerships.

BOSTON, MA, UNITED STATES, September 23, 2026 /EINPresswire.com/ — UltraSight™, a leader in AI-guided cardiac workflows with its Echosystem platform, today announced it has raised $24 million in Series B2 financing. The financing will support UltraSight’s commercial expansion in the United States and fund the development of new high-value workflows for the intensive care unit and circulatory support settings, where time-critical imaging decisions directly shape patient management. The proceeds will also support strategic collaborations to expand adoption of the Echosystem product line as it integrates proprietary AI innovations across time-critical cardiac care pathways.

Read the Full Release

Publish date

September 23, 2026